Pharma deals boost revenue at London-listed Sensyne

Deals with major pharmaceutical companies have boosted revenue at clinical AI company Sensyne Health. The London-listed company reported revenue of £2.1m for the year ended 30 April 2020 against £0.1m in 2019, after signing a £5m pharmaceutical deal with Bayer, followed by additional contracts with Roche and Alexion. It said the deals provided ‘significant validation’ of…

You must be a HM Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »